<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188057</url>
  </required_header>
  <id_info>
    <org_study_id>R06-0303</org_study_id>
    <nct_id>NCT01188057</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Non-fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam&#xD;
      Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2&#xD;
      mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs&#xD;
      Inc.Â®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult&#xD;
      volunteers administered under non-fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: This was a single-center, randomized, two-way&#xD;
      crossover study conducted under non-fasting conditions Official Title: A Relative&#xD;
      Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets under Non-Fasting&#xD;
      Conditions&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>72hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIRAVAM TM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIRAVAM TM 2 mg orally disintegrating tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG</intervention_name>
    <description>A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions</description>
    <arm_group_label>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS</arm_group_label>
    <other_name>NIRAVAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIRAVAM TM 2 mg orally disintegrating tablets, single dose</intervention_name>
    <description>B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions</description>
    <arm_group_label>NIRAVAM TM</arm_group_label>
    <other_name>ALPRAZOLAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who met the following criteria were included in the study.&#xD;
&#xD;
          1. Volunteers who were informed of the nature of the study and who read, reviewed, and&#xD;
             signed the informed consent prior to Period I dosing.&#xD;
&#xD;
          2. Volunteers who completed the screening process within 28 days prior to Period I&#xD;
             dosing.&#xD;
&#xD;
          3. Volunteers who were healthy adult men and women 18 years of age or older at the time&#xD;
             of dosing.&#xD;
&#xD;
          4. Volunteers who had a body mass index (BMI) between 18-32 kg/nr', inclusive, and&#xD;
             weighed at least 110 lbs.&#xD;
&#xD;
          5. Volunteers who were healthy as documented by the medical history, physical examination&#xD;
             (including but may not be limited to an evaluation of the cardiovascular,&#xD;
             gastrointestinal, respiratory and central nervous systems), vital sign assessments,&#xD;
             12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general&#xD;
             observations. Any abnormalities/deviations form the normal range that were considered&#xD;
             clinically relevant by the study physician and investigator were evaluated for&#xD;
             individual cases, documented in study files, and agreed upon by both the study&#xD;
             physician and investigator prior to enrolling the volunteer in this study and for&#xD;
             continued enrollment.&#xD;
&#xD;
          6. Female volunteers ofpostmenopausal (no menses) status for at least 1 year and has a&#xD;
             serum FSH level 2: 30 mlU/mL or surgically sterile (bilateral tubal ligation,&#xD;
             bilateral oophorectomy, or hysterectomy.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who met any ofthe following criteria were excluded from the study.&#xD;
&#xD;
          1. Volunteers who reported receiving any investigational drug within 28 days prior to&#xD;
             Period I dosing.&#xD;
&#xD;
          2. Volunteers who reported any presence or history of a clinically significant disorder&#xD;
             involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic,&#xD;
             hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined&#xD;
             by the clinical investigator(s).&#xD;
&#xD;
          3. Volunteers whose clinical laboratory test values outside the accepted reference range&#xD;
             and, when confirmed on re-examination, were deemed clinically significant.&#xD;
&#xD;
          4. Volunteers who demonstrated a reactive screen for hepatitis B surface antigen,&#xD;
             hepatitis C antibody, or HIV antibody.&#xD;
&#xD;
          5. Volunteers who reported a history of allergic response(s) to alprazolam or related&#xD;
             drugs.&#xD;
&#xD;
          6. Volunteers who reported the use of any systemic prescription medication in the 14 days&#xD;
             prior to Period I dosing.&#xD;
&#xD;
          7. Volunteers who reported the use of any drug known to induce or inhibit hepatic drug&#xD;
             metabolism in the 28 days prior to Period I dosing.&#xD;
&#xD;
          8. Volunteers who reported a history ofclinically significant allergies including drug&#xD;
             allergies.&#xD;
&#xD;
          9. Volunteers who reported a clinically significant illness during the 4 weeks prior to&#xD;
             Period I dosing (as determined by the clinical investigators).&#xD;
&#xD;
         10. Volunteers who reported a history of drug or alcohol abuse addiction or abuse within&#xD;
             the past year.&#xD;
&#xD;
         11. Volunteers who demonstrated a positive drug abuse screen for this study prior to&#xD;
             Period I dose administration.&#xD;
&#xD;
         12. Volunteers who currently used tobacco products.&#xD;
&#xD;
         13. Volunteers who reported donating greater than 150 mL ofblood within 28 days prior to&#xD;
             Period I dosing. All subjects were advised not to donate blood for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
         14. Volunteers who donated plasma (e.g. plasmapheresis) within 14 days prior to Period I&#xD;
             dosing. All subjects were advised not to donate plasma for four weeks after completing&#xD;
             the study&#xD;
&#xD;
         15. Volunteers who demonstrated a positive pregnancy screen (females only).&#xD;
&#xD;
         16. Volunteers who were currently pregnant or breastfeeding (females only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Carlson,, Pharm.D,</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>ALPRAZOLAM</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

